OptimizeRx Corp — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
▼ Likely negative
significance 42/100
What the filing says
OptimizeRx terminated Chief Commercial Officer Theresa Greco effective June 15, 2026, citing cost reduction and organizational realignment. Total severance: $380,000 base pay (24 monthly installments of $15,833) + $209,000 bonus lump sum + up to 12 months COBRA premium reimbursement + continued vesting of 56,160 equity shares through June 2027 as advisor. Greco released all employment claims; company retains non-disparagement and confidentiality covenants.
Why this rating
Departure of CCO signals cost-cutting pressure; ~$589K severance + equity acceleration = ~0.24% of $240.9M market cap. Material for senior leadership but not transformational. Ongoing advisor role limits disruption.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.